scholarly journals Clinical Applications of Natriuretic Peptides in Assessment of Valvular Heart Disease

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Abhishek Sharma ◽  
Vaseem Ahmed ◽  
Aakash Garg ◽  
Chirag Aggarwal
Keyword(s):  
Heart Disease ◽  
Natriuretic Peptides ◽  
Valvular Heart Disease ◽  
Clinical Utility ◽  
Surgical Intervention ◽  
Clinical Applications ◽  
Asymptomatic Patients ◽  
Routine Surveillance ◽  
Valvular Lesions

Biomarkers such as natriuretic peptides (NPs) have evolving clinical utility beyond the scope of heart failure. The role of NPs in the management of valvular heart disease is a growing area of investigation. NPs have much potential in the assessment of asymptomatic patients with hemodynamically significant valvular lesions who have traditionally been excluded from consideration of surgical intervention. NPs also have a role in the risk stratification of these patients as well as in routine surveillance and monitoring. Together with echocardiographic data and functional status, NPs are being incorporated into the management of valvular heart disease. In this review we examine the evidence for the role of natriuretic peptides in assessment of VHD.

The Role of Biomarkers in Valvular Heart Disease: Focus on Natriuretic Peptides

2014 ◽  
Vol 30 (9) ◽  
pp. 1027-1034 ◽  
Author(s):  
Jutta Bergler-Klein ◽  
Mariann Gyöngyösi ◽  
Gerald Maurer
Keyword(s):  
Heart Disease ◽  
Natriuretic Peptides ◽  
Valvular Heart Disease ◽  
Disease Focus

scholarly journals The Emerging Role of Exercise Testing and Stress Echocardiography in Valvular Heart Disease

2009 ◽  
Vol 54 (24) ◽  
pp. 2251-2260 ◽  
Author(s):  
Eugenio Picano ◽  
Philippe Pibarot ◽  
Patrizio Lancellotti ◽  
Jean Luc Monin ◽  
Robert O. Bonow
Keyword(s):  
Heart Disease ◽  
Exercise Testing ◽  
Valvular Heart Disease ◽  
Stress Echocardiography

scholarly journals Role of Serotoninergic Pathways in Drug-Induced Valvular Heart Disease and Diagnostic Features by Echocardiography

2009 ◽  
Vol 22 (8) ◽  
pp. 883-889 ◽  
Author(s):  
Sakima A. Smith ◽  
Alan D. Waggoner ◽  
Lisa de las Fuentes ◽  
Victor G. Davila-Roman
Keyword(s):  
Heart Disease ◽  
Valvular Heart Disease ◽  
Drug Induced ◽  
Diagnostic Features

Community prevalence, mechanisms and outcome of mitral or tricuspid regurgitation

Heart ◽  
2021 ◽  
pp. heartjnl-2020-318482
Author(s):  
Thomas J Cahill ◽  
Anthony Prothero ◽  
Jo Wilson ◽  
Andrew Kennedy ◽  
Jacob Brubert ◽  
...  
Keyword(s):  
Heart Disease ◽  
Tricuspid Regurgitation ◽  
Valvular Heart Disease ◽  
Surgical Intervention ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Age Dependent ◽  
Study Population

ObjectiveThe study aims were (1) to identify the community prevalence of moderate or greater mitral or tricuspid regurgitation (MR/TR), (2) to compare subjects identified by population screening with those with known valvular heart disease (VHD), (3) to understand the mechanisms of MR/TR and (4) to assess the rate of valve intervention and long-term outcome.MethodsAdults aged ≥65 years registered at seven family medicine practices in Oxfordshire, UK were screened for inclusion (n=9504). Subjects with known VHD were identified from hospital records and those without VHD invited to undergo transthoracic echocardiography (TTE) within the Oxford Valvular Heart Disease Population Study (OxVALVE). The study population ultimately comprised 4755 subjects. The severity and aetiology of MR and TR were assessed by integrated comprehensive TTE assessment.ResultsThe prevalence of moderate or greater MR and TR was 3.5% (95% CI 3.1 to 3.8) and 2.6% (95% CI 2.3 to 2.9), respectively. Primary MR was the most common aetiology (124/203, 61.1%). Almost half of cases were newly diagnosed by screening: MR 98/203 (48.3%), TR 69/155 (44.5%). Subjects diagnosed by screening were less symptomatic, more likely to have primary MR and had a lower incidence of aortic valve disease. Surgical intervention was undertaken in six subjects (2.4%) over a median follow-up of 64 months. Five-year survival was 79.8% in subjects with isolated MR, 84.8% in those with isolated TR, and 59.4% in those with combined MR and TR (p=0.0005).ConclusionsModerate or greater MR/TR is common, age-dependent and is underdiagnosed. Current rates of valve intervention are extremely low.

Comparative Effects of Platelet Suppressant Drugs on Platelet Survival Time

1975 ◽  
Author(s):  
E. Genton ◽  
J. Ellis ◽  
P. Steele
Keyword(s):  
Heart Disease ◽  
Venous Thromboembolism ◽  
Valvular Heart Disease ◽  
Laboratory Tests ◽  
Drug Effect ◽  
Platelet Reactivity ◽  
In Vitro Tests ◽  
Platelet Survival

The important role of platelets in thrombosis makes inhibitors of their reactivity potentially useful therapeutically. A number of laboratory tests have been identified which measure platelet reactivity, but it is not clear which test and which drug effect will correlate with thrombosis and thrombosis prevention. Platelet survival (SURV) correlates with thromboembolism in patients with valvular heart disease and is shortened in several other diseases. Therefore, it is of interest to identify drugs which prolong shortened SURV. Patients with arterial and venous thromboembolism and shortened SURV (51Chromium) were treated with platelet suppressants and restudied after 12 weeks. Sulfinpyrazone prolonged SURV(2.4±.04 to 3.1 ±.06 days; p < 0.001; n = 94; average ± SEM; normal, 3.7±.04 days) and 68 (72%) had some prolongation and 39 (42%) had normalization (> 3.3 days). Dipyridamole (100 mg qd) combined with aspirin (1200 mg qd) prolonged SURV (2.6±.11 to 3.2±0.12 days; p < 0.001; n = 13) and 9 of 13 (69%) had prolongation and 6 (46%) had normalization. Clofibrate altered SURV (2.6±.09 to 3.4±.14days;p < 0.001; n = 12) and 10 of 12 (83% ) had prolongation and normalization occurred in 6 (50%). Aspirin (1200 mg qd), cyproheptadine (32 mg qd) and propranolol (160 mg qd) failed to alter SURV.Thus, of drugs which alter in vitro tests of platelet reactivity, only sulfinpyrazone, dipyridamole and clofibrate improve shortened SURV.

scholarly journals Clinical Utility and Prognostic Value of Appropriateness Criteria in Stress Echocardiography for the Evaluation of Valvular Heart Disease

2013 ◽  
Vol 6 (9) ◽  
pp. 987-992 ◽  
Author(s):  
Sanjeev Bhattacharyya ◽  
Vasilis Kamperidis ◽  
Benoy Nalin Shah ◽  
Isabelle Roussin ◽  
Navtej Chahal ◽  
...  
Keyword(s):  
Heart Disease ◽  
Valvular Heart Disease ◽  
Prognostic Value ◽  
Clinical Utility ◽  
Stress Echocardiography ◽  
Appropriateness Criteria

scholarly journals “A Tale of Two Cities”: Anticoagulation Management in Patients with Atrial Fibrillation and Prosthetic Valves in the Era of Direct Oral Anticoagulants

Medicina ◽  
2019 ◽  
Vol 55 (8) ◽  
pp. 437
Author(s):  
Giuseppe Palmiero ◽  
Enrico Melillo ◽  
Antonino Salvatore Rubino
Keyword(s):  
Atrial Fibrillation ◽  
Heart Disease ◽  
Valvular Heart Disease ◽  
Therapeutic Option ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Anticoagulation Management ◽  
Prosthetic Valves

Valvular heart disease and atrial fibrillation often coexist. Oral vitamin K antagonists have represented the main anticoagulation management for antithrombotic prevention in this setting for decades. Novel direct oral anticoagulants (DOACs) are a new class of drugs and currently, due to their well-established efficacy and security, they represent the main therapeutic option in non-valvular atrial fibrillation. Some new evidences are exploring the role of DOACs in patients with valvular atrial fibrillation (mechanical and biological prosthetic valves). In this review we explore the data available in the medical literature to establish the actual role of DOACs in patients with valvular heart disease and atrial fibrillation.

Sign in / Sign up

Export Citation Format

Share Document